Table 1.

Showing clinical characteristics and PTGR1 IHC state. Ns = not significant, **** = p-value < 0.0001. ^#Two patients started immunotherapy as first-line treatment; one terminated treatment after 2 cycles due to toxicity, and the other after 3 cycles due to disease progression. Both patients received Carboplatin directly afterward and were therefore included in this cohort. Age is defined at baseline 1st line treatment.

	All	PTGR1.IHC.NEG	PTGR1.IHC.POS	p-value
Gender
Female	22 (31%)	14 (19.7%)	8 (11.3%)	ns
Male	49 (69%)	28 (39.4%)	21 (29.6%)
Age in years – median (range)	72.7 (48.7–86.8)	72.6 (48.7–86.8)	73.2 (49.6–82.2)	ns
Primary tumor location
Bladder	54 (76.1%)	30 (42.3%)	24 (33.8%)	ns
Renal pelvis or ureter	16 (22.5%)	11 (15.5%)	5 (7.0%)
Urethra	1 (1.4%)	1 (1.4%)	0 (0.0%)
Histology
Sarcomatoid differentiation	1 (1.4%)	0 (0.0%)	1 (1.4%)	ns
Squamous cell differentiation	2 (2.8%)	2 (2.8%)	0 (0.0%)
Urothelial carcinoma (predominantly)	68 (95.8%)	40 (56.3%)	28 (39.4%)
Smoke
Current Smoker	25 (35.2%)	13 (18.3%)	12 (16.9%)	ns
Former Smoker (> 7 days cessation)	34 (47.9%)	21 (29.6%)	13 (18.3%)
Never Smoker	12 (16.9%)	8 (11.3%)	4 (5.6%)
ECOG PS
0	39 (54.9%)	21 (29.6%)	18 (25.4%)	ns
1	28 (39.4%)	18 (25.4%)	10 (14.1%)
2	4 (5.6%)	3 (4.2%)	1 (1.4%)
First line treatment after biopsy #
Atezolizumab	1 (1.4%)	0 (0.0%)	1 (1.4%)	ns
Carboplatin based	34 (47.9%)	19 (26.8%)	15 (21.1%)
Cisplatin based	27 (38.0%)	16 (22.5%)	11 (15.5%)
Cisplatin/Carboplatin based (platin shift)	8 (11.3%)	6 (8.5%)	2 (2.8%)
Pembrolizumab	1 (1.4%)	1 (1.4%)	0 (0.0%)
PTGR-1 RNA count (optimized by IHC positivity)
PTGR1 count high	34 (47.9%)	6 (8.5%)	28 (39.4%)	****
PTGR1 count low	37 (52.1%)	36 (50.7%)	1 (1.4%)